Alumis Inc. (ALMS)
NASDAQ:ALMS
ALMS Stock Chart & Stats
$23.07
-$0.47(-5.84%)
At close: 4:00 PM EST
$23.07
-$0.47(-5.84%)
Day’s Range― - ―
52-Week Range$2.76 - $30.60
Previous CloseN/A
Volume29.29K
Average Volume (3M)1.36M
Market Cap
$3.05B
Enterprise Value$2.86B
Total Cash (Recent Filing)$308.50M
Total Debt (Recent Filing)$36.91M
Price to Earnings (P/E)―
Beta-1.59
Next Earnings
May 20, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding117,506,000
10 Day Avg. Volume1,577,289
30 Day Avg. Volume1,358,737
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)27.54
Price to Sales (P/S)345.07
P/FCF Ratio-22.42
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue119.03
Enterprise Value/Gross Profit123.48
Enterprise Value/Ebitda-6.91
Forecast
1Y Price Target
$39.89Price Target Upside72.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.95
Revenue Forecast (FY)$7.89M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyAnalyst notes Phase 3 topline results showing Envudeucitinib delivered deeper skin clearance than other oral therapies, suggesting a meaningful efficacy advantage that could support higher adoption.
Data Presentation CatalystAnalyst identifies the upcoming full Phase 3 dataset presentation at a major dermatology meeting as a catalyst that will allow detailed assessment of comparator-adjusted responses and could prompt a re-evaluation of the stock.
Regulatory Validation And Franchise ExpansionAnalyst highlights that approval of another TYK2 therapy for joint disease validates the mechanism and increases confidence that Envudeucitinib could expand into psoriatic arthritis and systemic lupus, enlarging commercial potential.
Bears Say
Competitive Landscape And Market UptakeAnalyst cautions that Envudeucitinib faces intense competition from established biologic injectables and other oral therapies, and patient preference for long-acting injectables could constrain oral uptake.
Data TransparencyAnalyst warns that limited topline disclosure and omission of placebo and comparator response rates make it difficult to assess placebo-adjusted benefit, creating uncertainty about the true drug advantage.
Development And Regulatory RiskAnalyst points to risks such as failure to obtain approvals in key markets, regulatory delays, and the potential need for additional financing that could dilute shareholders and impede commercialization.
Alumis Inc. News
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $2.76 and its highest was $30.60 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $3.05B.
When is Alumis Inc.’s upcoming earnings report date?
Alumis Inc.’s upcoming earnings report date is May 20, 2026 which is in 54 days.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on Mar 19, 2026. The company reported -$0.88 earnings per share for the quarter, beating the consensus estimate of -$0.923 by $0.043.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate is -0.77.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 117,506,000 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of -$0.88 in its last earnings report, beating expectations of -$0.923. Following the earnings report the stock price went down -1.261%.
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alumis Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.89 (72.91% Upside)
$39.89 (72.91% Upside)
Blogger Sentiment
Bearish
ALMS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $31.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Positive
20 days / 200 days
Momentum
511.12%
12-Months-Change
Fundamentals
Return on Equity
-72.65%
Trailing 12-Months
Asset Growth
22.04%
Trailing 12-Months
Company Description
Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS Stock 12 Month Forecast
Average Price Target
$39.89
▲(72.91% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---